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Abstract
Background: Previous studies on the effects of Statins in preventing atrial fibrillation (AF) after
cardiac surgery have shown conflicting results. Whether statins prevent AF in patients treated with
postoperative beta blockers and whether the statin-effect is dose related are unknown.
Methods: We retrospectively studied 1936 consecutive patients who underwent coronary artery
bypass graft (CABG) (n = 1493) or valve surgery (n = 443) at the Minneapolis Veterans Affairs
Medical Center. All patients were in sinus rhythm before the surgery. Postoperative beta blockers
were administered routinely (92% within 24 hours postoperatively).
Results: Mean age was 66+10 years and 68% of the patients were taking Statins. Postoperative AF
occurred in 588 (30%) patients and led to longer length of stay in the intensive care unit versus
those without AF (5.1+7.6 days versus 2.5+2.3 days, p < 0.0001). Patients with a past history of AF
had a 5 times higher risk of postoperative AF (odds ratio 5.1; 95% confidence interval 3.4 to 7.7; p
< 0.0001). AF occurred in 31% of patients taking statins versus 29% of the others (p = 0.49). In
multivariable analysis, statins were not associated with AF (odds ratio (OR) 0.93, 95% confidence
interval (CI) 0.7 to 1.2; p = 0.59). However, in a subgroup analysis, the patients treated with
Simvastatin >20 mg daily had a 36% reduction in the risk of postoperative AF (OR 0.64, 95% CI
0.43 to 0.6; p = 0.03) in comparison to those taking lower dosages.
Conclusion: Among cardiac surgery patients treated with postoperative beta blockers Statin
treatment reduces the incidence of postoperative AF when used at higher dosages
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Background
Postoperative atrial fibrillation (AF) occurs after 30-40%
of cardiac surgeries [1-3] and is associated with increased
risk of stroke [2-5], longer hospitalization, higher cost [4-
6] and greater risk of long-term mortality [7]. Beta block-
ers [8-12] and amiodarone [13-15] are known to reduce
the incidence of postoperative AF after cardiac surgery but
the effects of statins have been less conclusive [16]. While
statin treatment appeared to lower the risk of postopera-
tive AF in some initial observational studies [17-21] no
benefit was noted in a recent, well-conducted cohort of
>4000 patients [22]. In the only randomized clinical trial
in this arena, Atorvastatin, started 7 days before cardiac
surgery, was associated with a > 60% reduction in the inci-
dence of postoperative AF among 200 patients undergo-
ing coronary artery bypass graft (CABG) surgery [23].
However, the extraordinarily high AF rate (~60%) in the
control group of this study was not representative of the
experience at most centers [3,17-21]. Furthermore, beta
blockers, which unequivocally reduce postoperative AF,
were not administered routinely after surgery and the
number of patients undergoing concomitant valve surgery
was small (n = 41). Whether statin treatment prevents AF
among patients receiving postoperative beta blockers is
still unknown. Also, whether the statin effect on postoper-
ative AF is dosage dependent is unclear. Thus, the aim of
the present investigation was to fill these gaps in knowl-
edge in a large cohort of patients undergoing CABG or
valve surgery.
Methods
Study population
This study was approved by the human studies subcom-
mittee of the Research and Development Committee of
the Minneapolis Veterans Affairs (VA) Medical Center.
Individual consent was waived. A total of 2207 patients
underwent CABG or valve surgery (with or without con-
comitant CABG) at the Minneapolis VA Medical Center
between February 1999 and November 2005. Of these,
271 patients were excluded because of permanent preop-
erative AF (n = 131) or missing/uninterpretable electro-
cardiograms (ECG). A total of 1,936 patients were
included in the final analysis, including those with a pre-
vious history of AF who were in sinus rhythm at the time
of surgery (n = 114).
Data Collection
Preoperative clinical variables, procedural details and lab-
oratory test results were retrospectively abstracted from
the patients' electronic medical records and the VA Con-
tinuous Improvement in Cardiac Surgery Program, which
is an ongoing database of prospectively-collected data in
all patients undergoing heart surgery within the VA system
[24-27]. Pre and postoperative medications, including
statins and beta blockers, were obtained from the VA
pharmacy database and further confirmed by the clinician
notes in the electronic medical records. The use of VA
pharmacy refill data as a measure of actual medication use
has previously been validated [28,29]. At our institution
all preoperative medications are continued postopera-
tively and all patients receive beta blockers within 24
hours after surgery, unless contraindicated. The peri-oper-
ative ECGs were obtained from the ECG laboratory data-
base at the Minneapolis VA Medical Center.
Ascertainment of atrial fibrillation
The primary outcome variable was development of AF
within 30 days after the cardiac surgery. Postoperatively,
cardiac rhythm was continuously monitored for the first
72 to 96 hours in the intensive care and the telemetry step-
down units. Subsequently, 12-lead ECGs were performed
routinely on a daily basis and when clinically-indicated
until patients were discharged from the hospital. A follow-
up ECG was performed at 30-days after hospital dis-
charge. All ECGs were interpreted by two physicians (ASM
and MSA). Additional revisions were performed by a car-
diologist (ASA) when necessary.
Data analysis
All statistical analyses were performed using SPSS (version
16). Distribution of variables in the study cohorts were
summarized as mean + one standard deviation when nor-
mally distributed or median and interquartile range if
skewed. We compared baseline characteristics of the statin
treated and untreated patients, using t test for continuous
variables and likelihood ratio X2 tests for categorical vari-
ables. Logistic regression analysis was used to determine
the odds ratio (OR) of AF in association with statin treat-
ment. Multivariable logistic regression models included
the baseline differences between the statin and non-statin
groups and predictors known to be associated with post-
operative AF. Thus the predictor variables in our multivar-
iable models were age, body mass index, prior history of
AF, chronic lung disease, diabetes mellitus, hypertension,
left ventricular function, peripheral and cerebral vascular
disease, smoking status, history of myocardial infarction,
New York Heart Association functional class, beta blocker
treatment status, calcium channel blocker treatment, dig-
oxin treatment, cardiomegaly, surgical procedure, cross-
clamp time and statin treatment status. As a separate anal-
ysis a propensity score for taking statin was created for
each patient using the variables that were different
between the statin-treated and untreated groups. Multi-
variable models including the propensity score were cre-
ated to assess the statin effect on AF.
Predetermined subgroup analyses were performed to
assess statin effect in patients undergoing CABG surgery
only and to investigate whether the AF incidence wasJournal of Cardiothoracic Surgery 2009, 4:61 http://www.cardiothoracicsurgery.org/content/4/1/61
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related to the dosage of Statin. A p-value of < 0.05 was
considered statistically significant.
Results
Patient Characteristics
The baseline characteristics of the 1936 cardiac surgery
patients in relation to preoperative statin treatment are
outlined in Table 1. Mean age was 66+10 years and risk
factors known to be associated with postoperative AF were
prevalent (Table 1). A total of 1322 (68%) patients were
treated with statins pre- and postoperatively. Of these,
1205 were taking Simvastatin (mean dosage 33+22 mg;
range 5 to 80 mg). The patients receiving statin treatment
were younger, had a higher prevalence of coronary risk
factors and were more likely to undergo CABG in compar-
ison to those not taking statins (Table 1). On the other
hand, statin-untreated patients were more likely to have
left ventricular dysfunction, cardiomegaly and symptoms
of heart failure.
Of the 1936 surgical procedures, 1493 (77%) were CABG
only (Table 2). Postoperatively, 1778 (92%) of the
patients received beta-blockers within the 1st 24 hours
after surgery.
Postoperative AF
A total of 588 (30%) patients developed postoperative AF
after a median 2 days (range 1 to 29 days) following car-
diac surgery. Postoperative beta blocker use (p = 0.01),
cardiomegaly (p = 0.01), and previous history of AF (p =
0.001) were associated with AF. Patients with a previous
history of AF had a 5 times higher incidence of postoper-
ative AF (odds ratio 5.1; 95% confidence interval 3.4 to
7.7; p < 0.0001) compared to those without a prior his-
tory. Patients who developed postoperative AF had a sig-
nificantly longer length of stay in the Intensive Care Unit
(5.1+7.6 days versus 2.5+2.3 days, p < 0.0001) than those
who maintained sinus rhythm.
Effect of Statins
Postoperative AF occurred in 31% of statin-treated
patients versus 29% of those not taking statins (p = 0.49).
In multivariable analysis, after adjusting for the differ-
ences between the statin and non-statin groups and for
predictors known to be associated with postoperative AF
Table 1: Baseline characteristics of the 1,936 cardiac surgery patients included in the study
Statin Treatment
All patients
n = 1936
Yes
n = 1322
No
n = 614
p value
Clinical data
Age [years] 66+10 65+10 67+10 0.01
Male, % 99% 99% 99% 0.46
BMI [kg/m2] 29.4+5.4 30+5.4 29+5.3 0.03
Diabetes mellitus, % 34% 35% 30% 0.03
Hypertension, % 60% 81% 73% 0.001
Chronic lung disease, % 23% 22% 26% 0.06
Peripheral vascular disease, % 30% 30% 30% 0.90
Cerebrovascular disease, % 22% 22% 21% 0.49
Current Smoking, % 68% 21% 17% 0.03
History of myocardial infarction, % 42% 46% 33% <0.0001
History of heart surgery, % 9% 9% 9% 0.82
LV ejection fraction <50%, % 41% 42% 47% 0.05
NYHA heart failure class III/IV, % 35% 33% 39% 0.01
History of atrial fibrillation, % 5.7% 6.3% 4.6% 0.13
Chronic kidney disease, % 3.7% 11% 13% 0.53
Cardiomegaly, % 27% 25% 31% 0.01
Preoperative medications
BetaBlockers, % 53% 57% 46% <0.0001
ACE-I or ARB, % 72% 73% 69% 0.59
Gemfibrozil, % 8% 8% 7% 0.59
Calcium Chanel blocker, % 21% 23% 17% 0.01
Amiodarone, % 16% 16% 17% 0.31
Diuretics, % 41% 40% 43% 0.13
Digoxin, % 8% 7% 12% <0.0001
Continuous variables are expressed as mean + SD or median with interquartile range
Abbreviations: LV: left ventricular; NYHA:New York Heart Association; ACE-I: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin 
Receptor Blocker;BMI: Body Mass IndexJournal of Cardiothoracic Surgery 2009, 4:61 http://www.cardiothoracicsurgery.org/content/4/1/61
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(full list under statistical methods), statin treatment was
not associated with the risk of postoperative AF (odds
ratio 0.93, 95% confidence interval 0.7 to 1.2; p = 0.59).
Results were similar after performing propensity matching
analysis, to adjust for baseline differences between the sta-
tin-treated and untreated groups. Results did not change
when the analysis was limited to patients who underwent
CABG only.
Effect of Statin dosage
The majority (91%) of our statin-treated patients were
taking Simvastatin. Of these 1205 patients treated with
Simvastatin, 668 (55%) were taking Simvastatin <20 mg
daily versus 537 treated with a higher dosage. Notably,
postoperative AF was less common among the patients
taking a higher dosage of statins versus those taking <20
mg/day (28% vs. 34%; p = 0.03). In multivariate analysis,
the patients treated with statins>20 mg daily had a 36%
reduction in the risk of postoperative AF (odds ratio 0.64,
95% confidence interval 0.43 to 0.6; p = 0.03) in compar-
ison to those taking Simvastatin <20 mg daily (results
similar with propensity matching).
Discussion
The aim of this investigation was to assess whether statins
prevented AF after CABG and/or valve surgery among
patients who were treated with beta blockers in the imme-
diate postoperative period. We found that postoperative
AF (~30% in our cohort) occurred more commonly in
those with a previous history of AF and was associated
with a longer length of stay in the Intensive Care Unit.
There was a 36% reduction in postoperative AF among
those who were treated with a higher dosage (i.e. > 20 mg/
day) of statins. However the incidence of postoperative AF
was not influenced by low dose statin treatment.
There has been a recent interest in using statins for pre-
venting postoperative AF after cardiac surgery, however,
the clinical results are mixed. Initial cohort studies in this
arena suggested that statin treatment was associated with
a 40% to 50% reduction in the incidence of postoperative
AF in patients undergoing CABG [17-21]. Further, in a
small randomized clinical trial of 200 statin-naïve
patients, Atorvastatin 40 mg, started 7 days prior to elec-
tive cardiac surgery, was associated with a > 60% reduc-
tion in the risk of postoperative AF in comparison to
placebo [23]. However, there were some limitations in
these studies. First, postoperative beta blockers were not
routinely administered and their use was not uniformly
reported. Second, only a few valve surgery patients were
included. Third, the AF rate in the placebo arm of the only
randomized clinical trial was extraordinarily high (57%).
Finally, the magnitude of benefit approaching 60% is con-
sidered unusually high with present medical treatments.
The positive findings in these studies were recently refuted
by a well-conducted cohort study of >4000 consecutive
patients undergoing CABG or valve surgery [22]. In this
study, Virani et al. found that statin treatment did not
influence the incidence of postoperative AF.
Our data shows that, when beta blockers are on board,
higher doses of statins were required to reduce the inci-
dence of postoperative AF. Previously, Lertsburapa et al
[17] and Kourliouros et al [18] had also found that higher
dose statins were associated with greater reduction in
postoperative AF. While our statin-treated patients were
predominantly taking Simvastatin, a combination of dif-
ferent statins were used in the other 2 studies suggesting
that the statin-effect is not brand specific.
The most notable difference between the previous studies
and the present investigation was the use of postoperative
beta blockers. Indeed, >90% of our patients were treated
with beta blockers within 24 hours of cardiac surgery.
Administering beta blockers after surgery reduce AF inci-
dence and withdrawal of preoperative beta blockers is one
of the strongest predictors of postoperative AF [8-12].
Thus, it is possible that the previous reports of substantial
Table 2: Details of the surgical procedures performed on the 1,936 study patients
Statin Treatment
All patients
n = 1936
Yes
n = 1322
No
n = 614
p value
CABG, % 77% 84% 62% <0.0001
Valve surgery, % 12% 7% 23% <0.0001
Combined CABG and valve surgery, % 9% 8% 12% <0.0001
Other surgical procedure, % 2% 1% 3% <0.0001
Off-pump surgery, % 5% 5% 5% 0.94
Urgent/emergent surgery, % 11% 12% 10% 0.20
Ischemic time [minutes] 92+40 90+38 95+42 0.04
Total CPB time [minutes] 137+51 134+50 140+53 0.08
Abbreviations: CABG: coronary artery bypass surgery; CBP: Cardiopulmonary bypassJournal of Cardiothoracic Surgery 2009, 4:61 http://www.cardiothoracicsurgery.org/content/4/1/61
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benefits with statins may have been confounded by sub-
optimal utilization of postoperative beta blockers, partic-
ularly in the early postoperative period.
Another notable difference between the current and past
study cohorts was in the number of valve surgery patients
included. Postoperative AF is more common after valve
surgery. Further, in contrast to patients undergoing CABG,
statins are not routinely clinically indicated in valve sur-
gery patients. Thus, assessment of statin effect on postop-
erative AF is particularly important among these patients.
Whereas, most previous studies were largely comprised of
patients undergoing CABG, almost 25% of our cohort and
>30% of the study cohort by Virani et al. underwent valve
surgery with or without concomitant CABG. We found no
evidence of reduction in postoperative AF with statins in
the subgroup of our cohort who had valve surgery.
There is suggestive evidence that statin treatment may
reduce non-surgical AF among patients with coronary
heart disease [30,31]. However, the mechanism remains
unknown and randomized clinical trial data are lacking.
Notably, in a large cohort study in which propensity scor-
ing was utilized to adjust for the baseline differences
between the statin and non-statin groups there was no
effect on AF incidence [32].
One of the strengths of our investigation was the size of
the study sample of nearly 2000 patients, of which ~30%
developed postoperative AF. This large sample afforded us
a greater statistical power to adjust for all of the measured
differences between the statin vs. no-statin groups and the
predictor variables that are known to be associated with
postoperative AF. Routine use of postoperative beta block-
ers and inclusion of a substantial number of valve surgery
patients are other notable strengths. On the other hand,
this study also has some limitations. The inherent short-
comings of retrospective cohort study design, including
baseline differences among study groups, cannot be com-
pletely avoided, by a large sample size and statistical
adjustment for the multiple variables. Further, the find-
ings in subgroup analyses, although pre-specified in this
case, should be considered as hypothesis generating.
Almost all of our study patients were male. Thus caution
should be exercised in extending these results to women.
Also, the duration of statin treatment was not known. It is
possible that the effect of statins on AF is dependent upon
the duration of statin-therapy.
Conclusion
In conclusion, in this large cohort of cardiac surgery
patients who were routinely treated with postoperative
beta blockers, 30% had postoperative AF associated with
a longer stay at the intensive care unit. Higher dose (but
not lower dose) statin treatment was associated with a
36% reduction in the risk of postoperative AF.
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